MindBio Therapeutics Co-Founders Appear in Leading Australian Financial News Publication Ahead of Medicinal Psychedelics Legalisation in Australia

• MindBio and Co-founders profiled in Australian Financial Review
• Regulatory changes in Australia arrive 1 July 2023
• CEO lands in Canada for investor and conference presentations

VANCOUVER, BC / ACCESSWIRE / June 9, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), is pleased to report that the Company and its Co-Founders Justin Hanka, Chief Executive Officer and Anoosh Manzoori, Co-Founder and Investor have been profiled in Australia's major financial news publication, The Australian Financial Review today.

Foto: Accesswire

See link to article here: https://www.afr.com/life-and-luxury/health-and-wellness/the-acid-test- ...

MindBio's LSD-Microdosing clinical trials have received much attention in a world first take-home LSD trial and for the significant top line results reported from its Phase 1 clinical trials completed in 2022. The news comes as MindBio Chief Executive Officer and Co-Founder Justin Hanka lands in Canada for investor presentations ahead of major industry conferences.

Two fully funded Phase 2 take-home LSD-Microdosing clinical trials

MindBio has two fully funded Phase 2 LSD-Microdosing clinical trials. The first trial focuses on Major Depressive Disorder, where 20 patients meeting DSM-V criteria will receive an open label 8-week LSD microdosing treatment regimen in a naturalistic at-home setting. This trial will serve as the basis for continuing a much larger Phase 2b triple-dummy, active placebo-controlled trial in depressed patients. The second trial explores the effectiveness of LSD-Microdosing in conjunction with Meaning Centred Psychotherapy in late-stage cancer patients experiencing emotional distress. This randomized, double-blind, and placebo-controlled trial will involve 40 participants and is set to begin recruiting participants for the trial shortly.

Australia heads towards medical legalisation of psychedelics on 1 July 2023

MindBio's ability to demonstrate the safety and efficacy of microdosing interventions in real-world settings is revolutionary for the industry. Regulators are seeking credible data to make special access approvals for psychedelic medicines, which have shown profound healing effects on patients with mental health conditions. Australia has recently advanced its regulatory framework by medically legalizing psilocybin and MDMA effective 1 July 2023. Conceivably, the surprising change in regulatory sentiment and allowing pre-Phase 3 use of a drug in Australia is due to the ineffectiveness of existing treatments to abate the escalating mental health crisis in Australia.